ANP Receptor Subtypes on Cells of the Aqueous Inflow and Outflow
Principal Investigator
Richard Crook, PhD
University of California, San Francisco
San Francisco, CA, USA
About the Research Project
Program
Award Type
Standard
Award Amount
$24,582
Active Dates
April 01, 1994 - March 31, 1995
Grant ID
G1994316
Summary
Recent genetic evidence has raised the possibility that a particular protein in the eye (a neuropeptide receptor, ANPR-A) could be involved in the etiology of juvenile glaucoma in one family. This project aims to identify the location of this protein in tissues in the front of the eye, and to determine how the function of this protein and related proteins are controlled by hormonal and other factors in the eye. An understanding of how this protein functions may provide insights into this form of glaucoma. The ANP receptor subtypes will be distinguished by subtype preferences for various natriuretic peptides resulting in guanylate cyclase activation and by binding of labeled ANP to intact cells. Regulation of ANP receptor subtype function will be studied by measuring the effects of various hormones, neurotransmitters and other activators of second messenger pathways on natriuretic peptide stimulation of guanylate cyclase and labeled ANP binding to intact cells.
Related Grants
National Glaucoma Research
Developing New Drugs for Glaucoma
Active Dates
January 01, 2026 - December 31, 2027
Principal Investigator
Pete Williams, PhD
Current Organization
Karolinska Institutet
Developing New Drugs for Glaucoma
Active Dates
January 01, 2026 - December 31, 2027
Principal Investigator
Pete Williams, PhD
Current Organization
Karolinska Institutet
National Glaucoma Research
Novel Mechanisms to Regulate Eye Pressure
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Colleen McDowell, PhD
Current Organization
University of Wisconsin-Madison
Novel Mechanisms to Regulate Eye Pressure
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Colleen McDowell, PhD
Current Organization
University of Wisconsin-Madison
National Glaucoma Research
Developing a New Glaucoma Treatment That Avoids Daily Drops
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Gavin Roddy, MD, PhD
Current Organization
Mayo Clinic, Rochester
Developing a New Glaucoma Treatment That Avoids Daily Drops
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Gavin Roddy, MD, PhD
Current Organization
Mayo Clinic, Rochester